-
2022-501238-52-00
10
2023-03-23
Heart failure due to systemic left ventricular systolic dysfunction
-
2023-507396-21-00
4
2023-03-16
transfusion-dependent α- or β-thalassemia or low-risk myelodysplastic
-
2022-502917-27-00
5
2023-03-07
Migraine
-
2022-501894-37-00
4
2023-03-02
prostate cancer
-
2024-518937-26-00
4
2023-02-21
Patients with non-metastatic muscle invasive bladder cancer
-
2023-507233-19-00
10
2023-02-16
Treatment of IgAN
-
2023-505634-94-00
10
2023-02-02
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythe
-
2022-502328-35-00
4
2023-01-30
Alpha (α)-thalassemia
-
2023-505065-91-00
4
2023-01-30
Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small C
-
2024-520119-41-00
4
2023-01-15
Previously untreated patients with diagnosis of HCL
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2022-500470-33-00
5
2022-11-14
Haemophilia
-
2024-510656-13-00
5
2022-11-08
Migraine
-
2023-504885-50-00
5
2022-11-07
Treatment of children with chronic kidney disease and proteinuria
-
2023-508425-28-00
4
2022-10-24
Chronic Inflammatory Demyelinating Polyneuropathy
-
2023-508129-28-00
9
2022-09-28
Pediatric patients with Philadelphia chromosome positive chronic myelo
-
2023-508868-30-00
5
2022-09-26
Treatment of stereotypical prolonged seizure
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2024-516974-31-00
4
2022-07-22
Patients with acute myeloid leukemia or myelodysplastic syndrome.
-
2024-510950-29-00
5
2022-07-21
Stereotypical prolonged seizure
-
2023-508852-21-00
4
2022-06-10
Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer
-
2024-515681-14-00
4
2022-05-02
Stage II (pT4)/III colorectal cancer with positive circulating tumor D
-
2023-509743-27-00
4
2022-04-29
Systemic sclerosis associated with interstitial lung disease